Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Profit After Tax (2016 - 2026)

Ocular Therapeutix has reported Profit After Tax over the past 14 years, most recently at -$88.6 million for Q1 2026.

  • For Q1 2026, Profit After Tax fell 38.34% year-over-year to -$88.6 million; the TTM value through Mar 2026 reached -$290.5 million, down 50.74%, while the annual FY2025 figure was -$265.9 million, 37.43% down from the prior year.
  • Profit After Tax for Q1 2026 was -$88.6 million at Ocular Therapeutix, down from -$64.7 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$516000.0 in Q3 2023 and troughed at -$88.6 million in Q1 2026.
  • A 5-year average of -$41.2 million and a median of -$36.5 million in 2024 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: surged 97.87% in 2023 and later tumbled 6972.29% in 2024.
  • Year by year, Profit After Tax stood at -$15.5 million in 2022, then plummeted by 88.01% to -$29.2 million in 2023, then plummeted by 65.6% to -$48.4 million in 2024, then plummeted by 33.62% to -$64.7 million in 2025, then plummeted by 37.06% to -$88.6 million in 2026.
  • Business Quant data shows Profit After Tax for OCUL at -$88.6 million in Q1 2026, -$64.7 million in Q4 2025, and -$69.4 million in Q3 2025.